Startup entity
acquisition is the sole category represented across all 1 tracked stories. TERN-701 is most often covered alongside Keytruda, which appears in 1 of these 1 story. At 8, the average consequence score sits above the same-window beat average of 6.6.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. TERN-701 is most often covered alongside Keytruda, which appears in 1 of these 1 story. At 8, the average consequence score sits above the same-window beat average of 6.6. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. We currently track 1 Startup story that mention TERN-701, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 46 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TERN-701. Shared-story counts are live from our verified record — not editorial picks.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
TERN-701 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
